Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cytosorbents Corp (CTSO)
NASDAQ:CTSO
Holding CTSO?
Track your performance easily
CTSO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.70 - $1.88
Previous Close$0.92
Volume160.23K
Average Volume (3M)127.33K
Market Cap
$48.25M
Enterprise Value$69.37M
Total Cash (Recent Filing)$5.69M
Total Debt (Recent Filing)$26.81M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Mar 06, 2025EPS Estimate
-$0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding54,679,569
10 Day Avg. Volume191,472
30 Day Avg. Volume127,334
Standard Deviation0.23
R-Squared0.02
Alpha-0.00676
Financial Highlights & Ratios
Price to Book (P/B)3.81
Price to Sales (P/S)1.27
Price to Cash Flow (P/CF)-4.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.99
Enterprise Value/Gross Profit4.05
Enterprise Value/Ebitda-3.49
Forecast
1Y Price Target
$2.00Price Target Upside118.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Cytosorbents News
PremiumCompany Announcements
Cytosorbents Announces Rights Offering for Stockholders
PremiumCompany Announcements
CytoSorbents Corporation’s Q3 2024 Financial Highlights
PremiumPre-Earnings
Is CTSO a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
New Product LaunchThe launch of PuriFi, a novel hemoperfusion pump, continues to go well with many evaluations ongoing.
Product Revenue GrowthProduct revenues of $8.6M represent an increase of 11% year-over-year.
Regulatory ProgressThe FDA has accepted the 510(k) De Novo application for DrugSorb-ATR, and it is now under review.
Bears Say
Financial PerformanceThe company's blended product gross margin for the quarter decreased to 61%, a significant drop from 72% in 3Q23 and 75% in 2Q24.
Regulatory ChallengesThe primary focus of the company remains the submission of a 510(k) De Novo application to the FDA, which may also require an additional study to confirm the STAR-T study results.
RevenueThe company reported total revenues of $9.4M for the quarter, falling short of the consensus estimated revenue of $10.4M.
---
Ownership Overview
6.51% Insiders
6.87% Mutual Funds
19.28% Other Institutional Investors
63.93% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CTSO FAQ
What was Cytosorbents Corp’s price range in the past 12 months?
Cytosorbents Corp lowest stock price was $0.70 and its highest was $1.88 in the past 12 months.
What is Cytosorbents Corp’s market cap?
Currently, no data Available
When is Cytosorbents Corp’s upcoming earnings report date?
Cytosorbents Corp’s upcoming earnings report date is Mar 06, 2025 which is in 75 days.
How were Cytosorbents Corp’s earnings last quarter?
Cytosorbents Corp released its earnings results on Nov 07, 2024. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of -$0.055 by -$0.025.
Is Cytosorbents Corp overvalued?
According to Wall Street analysts Cytosorbents Corp’s price is currently Undervalued.
Does Cytosorbents Corp pay dividends?
Cytosorbents Corp does not currently pay dividends.
What is Cytosorbents Corp’s EPS estimate?
Cytosorbents Corp’s EPS estimate is -$0.07.
How many shares outstanding does Cytosorbents Corp have?
Cytosorbents Corp has 54,830,147 shares outstanding.
What happened to Cytosorbents Corp’s price movement after its last earnings report?
Cytosorbents Corp reported an EPS of -$0.08 in its last earnings report, missing expectations of -$0.055. Following the earnings report the stock price went down -17.778%.
Which hedge fund is a major shareholder of Cytosorbents Corp?
Among the largest hedge funds holding Cytosorbents Corp’s share is Royce & Associates LLC. It holds Cytosorbents Corp’s shares valued at N/A.
---
Cytosorbents Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.00 (118.58% Upside)
$2.00 (118.58% Upside)
Hedge Fund Trend
Decreased
By 349.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $47.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.27%
12-Months-Change
Fundamentals
Return on Equity
-118.50%
Trailing 12-Months
Asset Growth
0.48%
Trailing 12-Months
Company Description
Cytosorbents Corp
CytoSorbents Corp. engages in the research and development of blood purification technology for the reduction of deadly uncontrolled inflammation in hospitalized patients. Its product include CytoSorb, ContrastSorb, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.
---
CTSO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook with strong revenue growth, significant reductions in operating expenses, and important regulatory progress for DrugSorb ATR. However, the decline in gross margins and decreased grant revenue are notable challenges. The sentiment leans towards optimism with strategic advancements in product development and market readiness.Read More>---
CTSO Stock 12 Month Forecast
Average Price Target
$2.00
▲(118.58% Upside)
Technical Analysis
Best Analysts Covering CTSO
1 Year
1 Year Success Rate
11/26 ratings generated profit
1 Year Average Return
+3.54%
initiated a buy rating 5 months ago
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 42.31% of your transactions generating a profit, with an average return of +3.54% per trade.
---